{"id":"first-placebo-than-tranexamic-acid","safety":{"commonSideEffects":[{"rate":null,"effect":"Thromboembolic events"},{"rate":null,"effect":"Nausea"},{"rate":null,"effect":"Diarrhea"},{"rate":null,"effect":"Headache"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Tranexamic acid is a competitive inhibitor of plasminogen and plasmin, which are key enzymes in the fibrinolytic cascade responsible for breaking down blood clots. By inhibiting these enzymes, tranexamic acid stabilizes fibrin clots and reduces excessive bleeding. It is commonly used to reduce blood loss in surgical procedures and manage bleeding disorders.","oneSentence":"Tranexamic acid inhibits fibrinolysis by blocking plasminogen activation, thereby reducing bleeding.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T01:12:47.257Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Reduction of blood loss in surgical procedures"},{"name":"Management of bleeding in hemophilia and other bleeding disorders"}]},"trialDetails":[{"nctId":"NCT07362992","phase":"EARLY_PHASE1","title":"Topical Tranexamic Acid to Reduce Blood Loss During Cesarean Delivery","status":"NOT_YET_RECRUITING","sponsor":"Wolfson Medical Center","startDate":"2026-01-01","conditions":"Cesarean Delivery, Postpartum Hemorrhage (PPH), Intraoperative Blood Loss","enrollment":112},{"nctId":"NCT04910464","phase":"PHASE3","title":"Early Tranexamic Acid and Modulating the Inflammatory Response in Sepsis","status":"RECRUITING","sponsor":"Assiut University","startDate":"2021-06-05","conditions":"Sepsis","enrollment":80},{"nctId":"NCT01643135","phase":"PHASE4","title":"Reduction Bleeding in Laminectomy With Double Doses of Tranexamic Acid","status":"COMPLETED","sponsor":"Mahidol University","startDate":"2012-06","conditions":"Bleeding","enrollment":78},{"nctId":"NCT01031992","phase":"PHASE3","title":"Tranexamic Acid and Epistaxis in Hereditary Hemorrhagic Telangiectasia (HHT)","status":"COMPLETED","sponsor":"University Hospital, Saarland","startDate":"2002-03","conditions":"Hereditary Hemorrhagic Telangiectasia","enrollment":23}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":212,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"phase_3","status":"active","brandName":"First placebo, than Tranexamic acid.","genericName":"First placebo, than Tranexamic acid.","companyName":"University Hospital, Saarland","companyId":"university-hospital-saarland","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Tranexamic acid inhibits fibrinolysis by blocking plasminogen activation, thereby reducing bleeding. Used for Reduction of blood loss in surgical procedures, Management of bleeding in hemophilia and other bleeding disorders.","enrichmentLevel":3,"visitCount":1,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}